These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33318061)

  • 1. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Calvo-Aranda E; Cañamares-Orbis I; Novella-Navarro M; Martinez-Alcala A; Ortega de la O MDC; Escobar-Rodriguez I; Sanchez-Aranda FM
    Ann Rheum Dis; 2023 Feb; 82(2):e34. PubMed ID: 33318061
    [No Abstract]   [Full Text] [Related]  

  • 2. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    De Santis M; Voza A; Savevski V; Badalamenti S; Cecconi M; Mantovani A; Selmi C
    Ann Rheum Dis; 2023 May; 82(5):e111. PubMed ID: 33593740
    [No Abstract]   [Full Text] [Related]  

  • 3. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Kaklamanos A; Karamichalos P; Vlachoyiannopoulos PG; Tzioufas AG
    Ann Rheum Dis; 2023 Jun; 82(6):e134. PubMed ID: 33903096
    [No Abstract]   [Full Text] [Related]  

  • 4. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Klopfenstein T; Gendrin V; Conrozier T; Gerazime A; Puyraveau M; Zayet S
    Ann Rheum Dis; 2023 Jul; 82(7):e153. PubMed ID: 34162593
    [No Abstract]   [Full Text] [Related]  

  • 5. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Charles P
    Ann Rheum Dis; 2023 May; 82(5):e108. PubMed ID: 33589440
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda
    Ramiro S; Mostard R; Landewé RB
    Ann Rheum Dis; 2023 Feb; 82(2):e35. PubMed ID: 33318060
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles.
    Smolen JS
    Ann Rheum Dis; 2023 May; 82(5):e110. PubMed ID: 33658235
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles.
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 May; 82(5):e109. PubMed ID: 33589439
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Klopfenstein
    Landewé RB; Ramiro S; Mostard RLM
    Ann Rheum Dis; 2023 Jul; 82(7):e154. PubMed ID: 34162596
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 Jun; 82(6):e135. PubMed ID: 33903095
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 May; 82(5):e112. PubMed ID: 33593737
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions.
    Landewé RBM; Ramiro S; Mostard RLM
    RMD Open; 2021 Mar; 7(1):. PubMed ID: 33790049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
    Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
    J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series.
    Basnet A; Shrestha MR; Thapa R; Tamang B; Shrestha A; Rawal P; Duwal Shrestha SK; Karki L; Rai SK
    JNMA J Nepal Med Assoc; 2022 Aug; 60(252):727-731. PubMed ID: 36705224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
    Cure E; Kucuk A; Cure MC
    Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The shortcomings of tocilizumab in COVID-19.
    Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
    Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab prescribing criteria for COVID-19 patients.
    Al-Qaaneh AM; Al-Ghamdi FH
    Hum Vaccin Immunother; 2021 Apr; 17(4):1128. PubMed ID: 33079613
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.
    Lebedeva A; Molodtsov I; Anisimova A; Berestovskaya A; Dukhin O; Elizarova A; Fitzgerald W; Fomina D; Glebova K; Ivanova O; Kalinskaya A; Lebedeva A; Lysenko M; Maryukhnich E; Misyurina E; Protsenko D; Rosin A; Sapozhnikova O; Sokorev D; Shpektor A; Vorobyeva D; Vasilieva E; Margolis L
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.